A recent study identifies Neural EGFL-like 2 (NELL2), a secreted protein, as a key regulator of bone homeostasis, offering potential therapeutic applications for osteoporosis. NELL2 promotes ...

A newly discovered receptor switch that boosts bone growth could transform how we treat osteoporosis, by stimulating the body’s own bone-building machinery using a targeted drug and even mechanical ...

A recent study identifies Neural EGFL-like 2 (NELL2), a secreted protein, as a key regulator of bone homeostasis, offering potential therapeutic applications for osteoporosis. NELL2 promotes ...

A multisite, international phase 2 trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation ...

Osteoporosis is a common disorder in which bones lose density and become more fragile. Over time, that raises the risk of ...

Scientists have identified a protein that blocks the activity of bone-forming cells (osteoblasts) by stopping them from maturing during the journey to sites of bone formation, a new study has found.